Clinical Trials Browser

Phase 1 × Hsp90 inhibitor KU757 × Clear all

NCT02721459 2026-03-02

XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma

Phase 1 Active not recruiting

Melanoma, Skin Neoplasms

NCT01657591 2023-01-19

Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma

Phase 1 Completed

Melanoma, Skin Neoplasms